To analyze the clinical effects of varying concentrations of bivalent and monovalent natalizumab, particularly in relation to PML risk and treatment efficacy, in multiple sclerosis patients undergoing treatment.
Key Findings:
Cases of natalizumab-associated PML exhibited lower bivalent natalizumab concentrations than expected, challenging previous assumptions about PML risk.
EID resulted in a significant decrease in both total and bivalent natalizumab levels, with over half of patients dropping below quantification thresholds, raising concerns about treatment adequacy.
Patients with wearing-off symptoms had lower bivalent natalizumab levels, suggesting a potential link that warrants further investigation.
Interpretation:
The findings suggest that lower bivalent natalizumab levels may be associated with increased risk of PML and wearing-off symptoms, indicating a need for further research to explore these associations and their clinical implications.
Limitations:
Small sample size for PML cases limits the ability to draw definitive conclusions and may introduce bias.
Need for larger cohorts to validate findings related to wearing-off symptoms and to assess the generalizability of results.
Conclusion:
The clinical significance of Fab-arm exchange in natalizumab therapy for MS remains uncertain, warranting further investigation into its implications for treatment efficacy and safety, particularly in larger, more diverse patient populations.
by Liza M.Y. Gelissen, Stefan P.H. van den Berg, Alyssa A. Toorop, Martijn T. Wijburg, Emma C. Tallantyre, Ninotska I.L. Derksen, Floris C. Loeff, Joep Killestein, Theo Rispens, Zoé L.E. van Kempen, the NEXT-MS study group
